A686
El texto subrayado se agregaría a la ley vigente. El texto tachado se eliminaría.
Skip to main content
Go to top ] is old law to be omitted.
LBD02193-01-5
Go to top
<link href="/styles/noscript_styles.css" rel="stylesheet"/>
Sitemap
Request Information
Directions and Maps
New York State Assembly
Speaker Carl E. Heastie
- Assembly Members
- Legislative Info
- Public Hearings
- Speaker's Press
- Assembly Reports
- Committees & More
- Bill Search Home
- Laws
- Legislative Calendar
- Public Hearing Schedule
- Assembly Calendars
- Assembly Committee Agenda
- Summary
- Actions
- Committee Votes
- Floor Votes
- Memo
- Text
- LFIN
- Chamber Video/Transcript
A00686 Summary:
| BILL NO | A00686 |
| SAME AS | SAME AS S00520 |
| SPONSOR | Solages |
| COSPNSR | Carroll P |
| MLTSPNSR | |
| Add ?2404-e, Pub Health L | |
| Ensures ovarian cancer survivors have the right to access screenings for health conditions. |
A00686 Text:
STATE OF NEW YORK ________________________________________________________________________ 686 2025-2026 Regular Sessions IN ASSEMBLY (Prefiled) January 8, 2025 ___________ Introduced by M. of A. SOLAGES -- read once and referred to the Commit- tee on Health AN ACT to amend the public health law, in relation to ensuring ovarian cancer survivors have the right to access screenings for health condi- tions The People of the State of New York, represented in Senate and Assem- bly, do enact as follows: 1 Section 1. The public health law is amended by adding a new section 2 2404-e to read as follows: 3 § 2404-e. Ovarian cancer; right to screenings. No person with a 4 personal history of ovarian cancer shall be denied genetic testing or 5 genomic tumor profiling for inherited germline mutations and acquired 6 somatic mutations, respectively. In general, such testing shall not be 7 subject to frequency caps or other limitations and shall include, but 8 not be limited to: 9 (a) genetic mutations in BRCA1 and BRCA2 genes; 10 (b) genetic mutations associated with Lynch syndrome; 11 (c) rearrangement analysis of all coding exons associated with ovarian 12 cancer; and 13 (d) additional mutations if medically necessary and appropriate, as 14 determined by the health care professional treating the individual. 15 § 2. This act shall take effect immediately. EXPLANATION--Matter in italics (underscored) is new; matter in brackets [Texto oficial de la Legislatura de New York. El formato se adaptó para leerlo en Ratifi.